Skip to main content
SpringerLink
Log in

Principles of economic evaluation in cancer screening

  • Chapter
Advances in Cancer Screening

Part of the book series: Cancer Treatment and Research ((CTAR,volume 86))

Abstract

Should high-risk women under the age of 50 be screened for breast cancer? What about women over 70? How often should cervical cytology be assessed? Should asymptomatic men have a prostate-specific antigen performed? Who, if anyone, should receive CA125 and transvaginal ultrasound screening for ovarian cancer? How often should stool occult blood testing and/or sigmoidoscopy be performed to screen for colorectal cancer?

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Drummond MF, Stoddart GL, Torrance GW. 1980. Principles of Economic Appraisal in Health Care. Oxford: Oxford University Press.

    Google Scholar 

  2. Eddy DM, Nugent FW, Eddy JF, et al. 1987. Screening for colorectal cancer in a high-risk population. Gastroenterology 92: 682–692.

    PubMed  CAS  Google Scholar 

  3. Task Force on Principles for Economic Analysis of Health Care Technology. 1995. Economic analysis of health care technology. Ann Intern Med 122: 61–70.

    Google Scholar 

  4. Bonsel GJ, Rutten FFH, Uyl-de Groot CA. 1993. Economic evaluation alongside cancer trials: methodological and practical aspects. Eur J Cancer 29a: s10-s14.

    Article  PubMed  Google Scholar 

  5. Drummond MF, Davies L. 1991. Economic analysis alongside clinical trials. Revisiting the methodological issues. Int J Technol Assessment Health Care 7: 561–573.

    Article  CAS  Google Scholar 

  6. Kramer BS, Gohagan J, Prorok PC, et al. 1993. A National Cancer Institute sponsored screening trial for prostatic, lung, colorectal, and ovarian cancers. Cancer 71: 589–593.

    Article  PubMed  CAS  Google Scholar 

  7. Evans RG, Robinson GC. 1980. Surgical day care: measurement of the economic payoff. CMAJ 123: 873–880.

    CAS  Google Scholar 

  8. Bonsel GJ, Klompmaker IJ, van’t Veer F, et al. 1990. Use of prognostic models for assessment of value of liver transplantation. Lancet 335: 493–497.

    Article  PubMed  CAS  Google Scholar 

  9. van Hout BA, Bonsel GJ, Habbema JDF, et al. 1993. Heart transplantation in the Netherlands. J Health Econ 12: 73–93.

    Article  PubMed  Google Scholar 

  10. Fahs MC, Mandelblatt J, Schechter C, et al. 1992. Cost effectiveness of cervical cancer screening for the elderly. Ann Intern Med 117: 520–527.

    PubMed  CAS  Google Scholar 

  11. Eddy DM. 1990. Screening for colorectal cancer. Ann Intern Med 113: 373–384.

    PubMed  CAS  Google Scholar 

  12. Eddy DM. 1989. Screening for breast cancer. Ann Intern Med 111: 389–399.

    PubMed  CAS  Google Scholar 

  13. Barry MJ, Mulley AG, Richter JM. 1987. Effect of workup strategy on the cost-effectiveness of fecal occult blood screening for colorectal cancer. Gastroenterology 93: 301–310.

    PubMed  CAS  Google Scholar 

  14. Eddy DM. 1988. The value of mammography screening in women under age 50 years. JAMA 259: 1512–1519.

    Article  PubMed  CAS  Google Scholar 

  15. Krahn MD, Mahoney JE, Eckman MH, et al. 1994. Screening for prostate cancer: a decision analytic view. JAMA 272: 781–786.

    Article  Google Scholar 

  16. Mushlin AI, Fintor L. 1992. Is screening for breast cancer cost-effective. Cancer 69: 1957–1962.

    Article  PubMed  CAS  Google Scholar 

  17. Finkler SA. 1982. The distinction between cost and charges. Ann Intern Med 96: 102–109.

    PubMed  CAS  Google Scholar 

  18. Eisenberg JM. 1989. Clinical economics: a guide to the economic analysis of clinical practices. JAMA 262: 2879–2886.

    Article  PubMed  CAS  Google Scholar 

  19. Carter R, Glasziou P, van Ootmarssen G, et al. 1993. Cost-effectiveness of mammographic screening in Australia. Aust J Public Health 17: 42–50.

    Article  PubMed  CAS  Google Scholar 

  20. Cooper BS, Rice DP. 1976. The economic costs of illness revisited. Soc Security Bull 39: 21–36.

    CAS  Google Scholar 

  21. Rice DP, Hodgson TA, Kopstein AN. 1985. The economic costs of illness: a replication and update. Health Care Fin Rev 7: 61–80.

    CAS  Google Scholar 

  22. O’Brien B, Viramontes JL. 1994. Willingness to pay: a valid and reliable measure of health state preference. Med Decision Making 14: 289–297.

    Article  Google Scholar 

  23. Robinson JC. 1986. Philosophical origins of the economic valuation of life. Milbank Q 64: 133–155.

    Article  PubMed  CAS  Google Scholar 

  24. Weinstein MC. 1990. Principles of cost-effective resource allocation in health care organizations. Int J Technol Assess Health Care 6: 93–103.

    Article  PubMed  CAS  Google Scholar 

  25. Detsky AS, Naglie IG. 1990. A clinician’s guide to cost-effectiveness analysis. Ann Intern Med 113: 147–154.

    PubMed  CAS  Google Scholar 

  26. Torrance GW, Feeny D. 1989. Utilities and quality-adjusted life years. Int J Technol Assess Health Care 5: 559–575.

    Article  PubMed  CAS  Google Scholar 

  27. Shepard DS, Weinstein MC. 1980. Utility functions for life years and health status. Oper Res 28: 206–224.

    Article  Google Scholar 

  28. Mehrez A, Gafni A. 1989. Quality adjusted life years, utility theory, and healthy year equivalents. Med Decision Making 9: 142–149.

    Article  CAS  Google Scholar 

  29. Torrance GW. 1987. Utility approach to measuring health-related quality of life. J Chron Dis 40: 593–600.

    Article  PubMed  CAS  Google Scholar 

  30. Weinstein M, Fineberg H. 1980. Clinical Decision Analysis. Philadelphia: WB Saunders.

    Google Scholar 

  31. Phelps C, Mushlin AI. 1991. On the (near) equivalence of cost-effectiveness and cost-benefit analyses. Int J Technol Assess Care 7: 12–21.

    Article  CAS  Google Scholar 

  32. Lerman C, Trock B, Rimer BK, et al. 1991. Psychological and behavioral implications of abnormal mammograms. Ann Intern Med 114: 657–661.

    PubMed  CAS  Google Scholar 

  33. Lerman C, Rimer BK, Trock B, et al. 1990. Factors associated with repeat adherence to breast cancer screening. Prev Med 19: 279–290.

    Article  PubMed  CAS  Google Scholar 

  34. Reelick NF, de Haes WF, Schuurman JH. 1984. Psychological side effects of the mass screening on cervical cancer. Soc Sci Med 18: 1089–1093.

    Article  PubMed  CAS  Google Scholar 

  35. Wilkinson GB, Meacham AR. 1991. Prostate cancer awareness week: how we did it. Urol Nursing 11: 19–20.

    Google Scholar 

  36. Greenwald HP, Becker SW, Nevitt MC. 1978. Delay and noncompliance in cancer detection: a behavioral perspective for health planners. Milbank Mem Fund Q Health Soc 56: 212–230.

    Article  PubMed  CAS  Google Scholar 

  37. Patterson DE, Zincke H. 1984. Perioperative complications of pelvic lymphadenectomy and radical retropubic prostatectomy in 150 patients. Urology 23: 243–246.

    Article  PubMed  CAS  Google Scholar 

  38. Morse RM, Spirnak P, Resnick MI. 1988. Iatrogenic colon and rectal injuries associated with urological intervention: report of 14 patients. J Urol 140: 101–103.

    PubMed  CAS  Google Scholar 

  39. Pilepich MV, Perez CA, Walz BJ, et al. 1981. Complications of definitive radiotherapy for carcinoma of the prostate. Int J Radiat Oncol Biol Phys 7: 1341–1348.

    Article  PubMed  CAS  Google Scholar 

  40. Herr HW. 1994. Quality of life of incontinent men after radical prostatectomy. J Urol 151: 652–654.

    PubMed  CAS  Google Scholar 

  41. Kornblith AB, Herr HW, Ofman US, et al. 1994. Quality of life of patients with prostate cancer and their spouses. The value of a data base in clinical care. Cancer 73: 2791–2802.

    Article  PubMed  CAS  Google Scholar 

  42. Schover LR. 1993. Sexual rehabilitation after treatment for prostate cancer. Cancer 71 (3 Suppl): 1024–1030.

    Article  PubMed  CAS  Google Scholar 

  43. Walsh PC, Donker PJ. 1982. Impotence following radical prostatectomy: insight into etiology and prevention. J Urol 128: 492–497.

    PubMed  CAS  Google Scholar 

  44. Schellhammer PF, el-Mahdi AM. 1990. Local failure and related complications after definitive treatment of carcinoma of the prostate by irradiation or surgery. Urol Clin North Am 17: 835–851.

    PubMed  CAS  Google Scholar 

  45. Schellhammer PF, Whitmore RB, Kuban DA, et al. 1989. Morbidity and mortality of local failure after definitive therapy for prostate cancer. J Urol 141: 567–571.

    PubMed  CAS  Google Scholar 

  46. Fossa SD, Aaronson N, Calais da Silva F, et al. 1989. Quality of life in patients with muscleinfiltrating bladder cancer and hormone-resistant prostatic cancer. Eur Urol 16: 335–339.

    PubMed  CAS  Google Scholar 

  47. Fossa SD, Aaronson N, de Voogt HJ, et al. 1990. Assessment of quality of life and subjective response criteria in patients with prostatic cancer. In EORTC Genitourinary Group Monograph 7: Prostate Cancer and Testicular Cancer. New York: Wiley-Liss, p. 199.

    Google Scholar 

  48. Fossa SD, Aaronson NK, Newling D, et al. 1990. Quality of life and treatment of hormone resistant metastatic prostatic cancer. Eur J Cancer 26: 1133–1136.

    Article  PubMed  CAS  Google Scholar 

  49. de Koning HJ, van Ineveld BM, van Ootmarssen GJ. 1991. Breast cancer screening and cost- effectiveness; policy alternatives, quality of life considerations and the possible impact of uncertain factors. Int J Cancer 49: 531–537.

    Article  PubMed  Google Scholar 

  50. Krahn M, Gafni A. 1993. Discounting in the evaluation of health care interventions. Med Care 31: 403–418.

    Article  PubMed  CAS  Google Scholar 

  51. Olson M, Bailey MJ. 1981. Positive time preference. J Polit Econ 81: 1–25.

    Article  Google Scholar 

  52. Fisher I. 1935. The Theory of Interest. London: Macmillan.

    Google Scholar 

  53. Baumol WJ. 1968. On the social rate of discount. Am Econ Rev 58: 788–802.

    Google Scholar 

  54. Feldstein MS. 1964. The social time preference discount rate in cost benefit analysis. Econ J 74: 360–379.

    Article  Google Scholar 

  55. Goodin RE. 1982. Discounting discounting. J Public Policy 2: 53–72.

    Article  Google Scholar 

  56. Pigou AC. 1920. The Economics of Welfare. London: Macmillan.

    Google Scholar 

  57. Keeler EB, Cretin S. 1983. Discounting of life saving and other non-monetary benefits. Management Sci 29: 300–306.

    Article  Google Scholar 

  58. Hillman AL, Kim M. 1994. Decision making in health care: discounting of life years revisited. PharmacoEcon 7: 198–205.

    Article  Google Scholar 

  59. Weinstein MC, Stason WB. 1977. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 296: 716–721.

    Article  PubMed  CAS  Google Scholar 

  60. Briggs A, Sculpher M, Buxton M. 1994. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Econ Ser 3: 95–104.

    Article  CAS  Google Scholar 

  61. Critchfield GC, Willard KE. 1986. Probabilistic analysis of decision trees using Monte Carlo simulation. Med Decision Making 6: 85–92.

    Article  CAS  Google Scholar 

  62. Willard KE, Critchfield GC. 1986. Probabilistic analysis of decision trees using symbolic algebra. Med Decision Making 6: 93–100.

    Article  CAS  Google Scholar 

  63. Doubilet P, Begg CB, Weinstein MC, et al. 1985. Probabilistic sensitivity analysis using Monte Carlo simulation. Med Decision Making 5: 157–177.

    Article  CAS  Google Scholar 

  64. Brown ML, Fintor L. 1993. Cost-effectiveness of breast cancer screening: preliminary results of a systematic review of the literature. Breast Cancer Res Treatment 25: 113–118.

    Article  CAS  Google Scholar 

  65. Nutting PA, Calonge BN, Iverson DC, et al. 1994. The danger of applying uniform clinical policies across populations: the case of breast cancer in American Indians. Am J Public Health 84: 1631–1636.

    Article  PubMed  CAS  Google Scholar 

  66. van Ineveld BM, Oortmarssen GJ, de Koning HJ, et al. 1993. How cost-effective is breast cancer screening in different EC countries? Eur J Cancer 29A: 1663–1668.

    Article  PubMed  Google Scholar 

  67. Sackett DL, Haynes RB, Guyatt GH, et al. 1991. Clinical Epidemiology: A Basic Science for Clinical Medicine, 2nd ed. Boston/Toronto/London: Little, Brown and Company.

    Google Scholar 

  68. Guyatt GH, Sackett DL, Cook DJ. 1994. User’s Guides to the Medical Literature 11. How to use an article about therapy of prevention B. What were the results and will they help me in caring for my patients? JAMA 271: 59–63.

    Article  PubMed  CAS  Google Scholar 

  69. Drummond M, Torrance G, Mason J. 1993. Cost-effectiveness league tables: more harm than good? Soc Sci Med 37: 33–40.

    Article  PubMed  CAS  Google Scholar 

  70. Laupacis A, Feeny D, Detsky AS, et al. 1993. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 148: 921–924.

    Google Scholar 

  71. Asch DA, Hershey JC. 1995. Why some health policies don’t make sense at the bedside. Ann Intern Med 122: 846–850.

    PubMed  CAS  Google Scholar 

  72. Ben-Zion U, Gafni A. 1983. Evaluation of public investment in health care: is the risk irrelevant? J Health Econ 2: 161–165.

    Article  PubMed  CAS  Google Scholar 

  73. Gafni A, Torrance GW. 1984. Risk attitude and time preference in health. Management Sci 30: 440–451.

    Article  Google Scholar 

  74. Arrow KJ, Lind RC. 1970. Uncertainty and the evaluation of public investment. Am Econ Rev 60: 364–378.

    Google Scholar 

  75. Shimbo T, Glick HA, Eisenberg JM. 1994. Cost-effectiveness analysis of strategies for colorectal cancer screening in Japan. Int J Technol Assess Care 10: 359–375.

    Article  CAS  Google Scholar 

Download references

Authors
  1. Murray Krahn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gary Naglie
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Toronto, Canada

    Anthony B. Miller

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Kluwer Academic Publishers

About this chapter

Cite this chapter

Krahn, M., Naglie, G. (1996). Principles of economic evaluation in cancer screening. In: Miller, A.B. (eds) Advances in Cancer Screening. Cancer Treatment and Research, vol 86. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1265-9_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-1265-9_3

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-8539-7

  • Online ISBN: 978-1-4613-1265-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation